Tweet CAMBRIDGE, MA, Generation Bio announced the closing of a $110 million Series C financing.

To export Generation Bio funding data to PDF and Excel, clickClick here for more funding data on Generation BioTo export Generation Bio funding data to PDF and Excel, click here Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing.

Generation Bio's non-viral platform moves beyond the limitations of existing gene therapy by enabling re-dosable long-lasting gene therapies for severe diseases on a global scale.

In addition to the liver, Generation Bio is developing gene therapies for patients with skeletal muscle and eye diseases.

Generation Bio was founded by Atlas Venture and is headquartered in Cambridge, Mass. | To read full story, visit https://startuparound.com/read/1578691807.5252938/Generation-Bio-Inks-$110M-Series-C-Financing?ref=audio_experience